NCT05045768View on ClinicalTrials.gov

Postinfectious Irritable Bowel Syndrome and Gelsectan

PHASE4CompletedINTERVENTIONAL

Enrollment

275

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

February 26, 2024

Study Completion Date

February 26, 2024

Conditions

Irritable Bowel Syndrome

Interventions

DRUG

(Gelsectan, Devintec Sagl)

Patients included in the study will receive for 28 days a capsule containing Xyloglucan, Pea Protein and Grape Seed Extract and a prebiotic Xylo-oligosaccharide (Gelsectan, Devintec sagl) twice daily.

Trial Locations (1)

10676

Evangelismos Hospital, Athens

All Listed Sponsors

lead

Evangelismos Hospital

OTHER

NCT05045768 - Postinfectious Irritable Bowel Syndrome and Gelsectan | Biotech Hunter | Biotech Hunter